Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kurata, Morito ^a,b   Rathe, Susan K ^a   Bailey, Natashay J ^a   Aumann, Natalie K ^a   Jones, Justine M ^a   Veldhuijzen, G Willemijn ^a   Moriarity, Branden S ^a,c   Largaespada, David A ^a,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTARABINE; DEOXYCYTIDINE KINASE; DEXAMETHASONE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GUIDE RNA; PREDNISOLONE;

ACUTE MYELOID LEUKEMIA; ANIMAL; CELL CLONE; CELL LINE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DRUG RESISTANCE; ENZYMOLOGY; GENE LIBRARY; GENE LOCUS; GENETIC SCREENING; GENETICS; HUMAN; HUMAN GENOME; IC50; METABOLISM; MOUSE; MUTATION; NUCLEOTIDE SEQUENCE; REPRODUCIBILITY; U-937 CELL LINE;

ANIMALS; BASE SEQUENCE; CELL LINE; CLONE CELLS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CYTARABINE; DEOXYCYTIDINE KINASE; DEXAMETHASONE; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENE LIBRARY; GENETIC LOCI; GENETIC TESTING; GENOME, HUMAN; GLUCOCORTICOIDS; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOID, ACUTE; MICE; MUTATION; PREDNISOLONE; RECEPTORS, GLUCOCORTICOID; REPRODUCIBILITY OF RESULTS; RNA, GUIDE; U937 CELLS;

EID: 84994201375     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36199     Document Type: Article

References (24)

1. Radich, J. P. Molecular classification of acute myeloid leukemia: are we there yet? J Clin Oncol 26, 4539-4541, doi: 10.1200/JCO.2008.16.4293 (2008).
2. Network, C. G. A. R. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368, 2059-2074, doi: 10.1056/NEJMoa1301689 (2013).
3. O'Donnell, M. R. et al. Acute myeloid leukemia. J Natl Compr Canc Netw 10, 984-1021 (2012).
4. Rathe, S. K. et al. Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia. Sci Rep 4, 6048, doi: 10.1038/srep06048 (2014).
5. Schmidt, S. et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11 Suppl 1, S45-S55, doi: 10.1038/sj.cdd.4401456 (2004).
6. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823, doi: 10.1126/science.1231143 (2013).
7. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87, doi: 10.1126/science.1247005 (2014).
8. Galmarini, C. M. et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117, 860-868 (2002).
9. Abraham, A. et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics 16, 877-890, doi: 10.2217/pgs.15.44 (2015).
10. Rathe, S. K. & Largaespada, D. A. Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines. Leukemia 24, 1513-1515, doi: 10.1038/leu.2010.88 (2010).
11. Di Santo, E. et al. A glucocorticoid receptor-independent mechanism for neurosteroid inhibition of tumor necrosis factor production. Eur J Pharmacol 299, 179-186 (1996).
12. Agarwai, M. K. The antiglucocorticoid action of mifepristone. Pharmacol Ther 70, 183-213 (1996).
13. Cadepond, F., Ulmann, A. & Baulieu, E. E. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48, 129-156, doi: 10.1146/annurev.med.48.1.129 (1997).
14. Song, J. H. et al. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int J Oncol 34, 1165-1171 (2009).
15. Damaraju, V. L. et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22, 7524-7536, doi: 10.1038/sj.onc.1206952 (2003).
16. Deans, R. M. et al. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nat Chem Biol 12, 361-366, doi: 10.1038/nchembio.2050 (2016).
17. Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588, doi: 10.1038/nature14136 (2015).
18. Schröder, J. K., Kirch, C., Seeber, S. & Schütte, J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 103, 1096-1103 (1998).
19. Galmarini, C. M. et al. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98, 1922-1926 (2001).
20. Martin, L. B., Brace, A. J., Urban, A., Coon, C. A. & Liebl, A. L. Does immune suppression during stress occur to promote physical performance? J Exp Biol 215, 4097-4103, doi: 10.1242/jeb.073049 (2012).
21. Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353, 1711-1723, doi: 10.1056/NEJMra050541 (2005).
22. Schaaf, M. J. & Cidlowski, J. A. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 83, 37-48 (2002).
23. Schlossmacher, G., Stevens, A. & White, A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 211, 17-25, doi: 10.1530/JOE-11-0135 (2011).
24. Frankfurt, O. & Rosen, S. T. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 16, 553-563 (2004).